Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 8/20 | 0.54 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.49 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652270 | 0.92 | EZH2 (0.47) | NPBWR1DGAT1KCNH2HDAC6CHEK2 | |
| SCHEMBL5647629 | 0.88 | GLA (0.53) | NPBWR1HDAC6EZH2GLA | |
| SCHEMBL5651959 | 0.88 | L3MBTL1 (0.47) | NPBWR1HDAC6CHEK2EZH2GLA | |
| SCHEMBL5649937 | 0.87 | GLA (0.45) | NPBWR1HDAC6EZH2GLA | |
| SCHEMBL5650733 | 0.85 | MEN1 (0.49) | HDAC6EZH2GLA | |
| SCHEMBL5648775 | 0.85 | CHEK2 (0.55) | CHEK2EZH2 | |
| SCHEMBL5651443 | 0.84 | EZH2 (0.57) | EZH2GLA | |
| SCHEMBL5650741 | 0.83 | MEN1 (0.49) | HDAC6EZH2GLA | |
| SCHEMBL5653127 | 0.83 | RHEB (0.58) | EZH2GLA | |
| SCHEMBL5649916 | 0.82 | MEN1 (0.52) | CHEK2EZH2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | NPBWR1 23/4885DGAT1 2386/4885KCNH2 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.